PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sunitinib Malate (SU011248)

First Posted Date: 2008-06-27

Last Posted Date: 2013-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 105

Registration Number: NCT00706706

Locations: 🇨🇳
Pfizer Investigational Site, Xi'an, China

Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study

Terminated

Conditions: Nonrestorative Sleep

Interventions: Procedure: PSG

First Posted Date: 2008-06-26

Last Posted Date: 2019-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT00705601

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Phase 3

Terminated

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: sorafenib
Drug: sunitinib malate

First Posted Date: 2008-06-18

Last Posted Date: 2013-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 1075

Registration Number: NCT00699374

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Completed

Conditions: Lymphoma, Mantle-Cell
Carcinoma, Renal Cell, Advanced
Gastrointestinal Stroma Tumors

Interventions: Drug: Sunitinib
Drug: Temsirolimus
Drug: Axitinib

First Posted Date: 2008-06-18

Last Posted Date: 2022-12-05

Lead Sponsor: Pfizer

Target Recruit Count: 1520

Registration Number: NCT00700258

Locations: 🇩🇪
Office of Detlef Muller, Bautzen, Germany
🇩🇪
Klotz, Weiden, Germany
🇩🇪
Carsten Lange, Bernburg, Germany

and more 74 locations

Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)

Completed

Conditions: Renal Transplantation

Interventions: Drug: Sirolimus

First Posted Date: 2008-06-13

Last Posted Date: 2014-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT00697112

Locations: 🇦🇷
Pfizer Investigational Site, Tucuman, Argentina

The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

Phase 2

Completed

Conditions: Cardiomyopathy

Interventions: Drug: Fx-1006A

First Posted Date: 2008-06-10

Last Posted Date: 2013-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00694161

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 3 locations

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

Phase 1

Completed

Conditions: Healthy
Non-Smoking

Interventions: Drug: varenicline
Drug: Placebo

First Posted Date: 2008-06-10

Last Posted Date: 2009-06-02

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT00694044

Locations: 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: AG-013736

First Posted Date: 2008-06-06

Last Posted Date: 2012-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00692341

Locations: 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States

Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Drug: placebo
Drug: varenicline

First Posted Date: 2008-06-05

Last Posted Date: 2015-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 659

Registration Number: NCT00691483

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

Completed

Conditions: Overactive Bladder
Urinary Incontinence

Interventions: Drug: fesoterodine

First Posted Date: 2008-06-05

Last Posted Date: 2018-11-02

Lead Sponsor: Pfizer

Target Recruit Count: 823

Registration Number: NCT00691093

Locations: 🇸🇰
Pfizer Investigational Site, Zvolen, Slovakia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy